--- title: "04:19 ETMereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO" type: "News" locale: "en" url: "https://longbridge.com/en/news/278845218.md" description: "Mereo BioPharma Group plc is facing a class action lawsuit for securities law violations, specifically for misleading investors regarding its Phase 3 ORBIT and COSMIC programs. The lawsuit claims that the company made false statements about the efficacy of these programs, which failed to meet their endpoints. Shareholders who purchased shares between June 5, 2023, and December 26, 2025, are encouraged to contact DJS Law Group for potential lead plaintiff appointments. The deadline for participation is April 6, 2026." datetime: "2026-03-12T08:20:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278845218.md) - [en](https://longbridge.com/en/news/278845218.md) - [zh-HK](https://longbridge.com/zh-HK/news/278845218.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278845218.md) | [繁體中文](https://longbridge.com/zh-HK/news/278845218.md) # 04:19 ETMereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO , /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. **CLASS PERIOD:** June 5, 2023 to December 26, 2025 **DEADLINE:** April 6, 2026 **CASE DETAILS:** According to the Complaint, the Company made false and misleading statements to the market. Mereo misled investors about its Phase 3 ORBIT and COSMIC programs. Both programs failed to achieve their endpoints against placebo or bisphosphonate control groups, respectively. Based on these facts, Mereo's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate. **WHY DJS LAW GROUP?** DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. **CONTACT:** David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: \[email protected\] SOURCE DJS Law Group LLP ### Related Stocks - [Mereo BioPharma Group plc (MREO.US)](https://longbridge.com/en/quote/MREO.US.md) ## Related News & Research - [01:13 ETMereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO](https://longbridge.com/en/news/279888293.md) - [Balanced Risk-Reward Amid Clinical Uncertainty: Maintaining Hold on Mereo BioPharma](https://longbridge.com/en/news/279838373.md) - [09:28 ETMREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026](https://longbridge.com/en/news/278731955.md) - [Weiss Ratings Reiterates Sell (D-) Rating for Mereo BioPharma Group (NASDAQ:MREO)](https://longbridge.com/en/news/260630257.md) - [Mereo BioPharma Group (NASDAQ:MREO) Releases Quarterly Earnings Results](https://longbridge.com/en/news/265408986.md)